Cargando…

Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients

AIM: To estimate the mean lifetime survival benefit, an essential component of health economic evaluations in oncology, of adding tumor treating fields (TTFields) to maintenance temozolomide (TMZ) for newly diagnosed glioblastoma patients. METHODS: We integrated EF-14 trial data with glioblastoma ep...

Descripción completa

Detalles Bibliográficos
Autores principales: Guzauskas, Gregory F, Salzberg, Marc, Wang, Bruce CM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200060/
https://www.ncbi.nlm.nih.gov/pubmed/30124334
http://dx.doi.org/10.2217/cns-2018-0010
_version_ 1783365265056071680
author Guzauskas, Gregory F
Salzberg, Marc
Wang, Bruce CM
author_facet Guzauskas, Gregory F
Salzberg, Marc
Wang, Bruce CM
author_sort Guzauskas, Gregory F
collection PubMed
description AIM: To estimate the mean lifetime survival benefit, an essential component of health economic evaluations in oncology, of adding tumor treating fields (TTFields) to maintenance temozolomide (TMZ) for newly diagnosed glioblastoma patients. METHODS: We integrated EF-14 trial data with glioblastoma epidemiology data. The model provided for an evidence-based approach to estimate lifetime survival for the material number of EF-14 trial patients still alive at 5 years. RESULTS & CONCLUSION: Patients treated with TTFields and TMZ had an incremental mean lifetime survival of 1.8 years (TTFields/TMZ: 4.2 vs TMZ alone: 2.4). Patients alive at year 2 after starting TTFields had a 20.7% probability of surviving to year 10. The results presented here provide the required incremental survival benefit necessary for a future assessment of the incremental cost–effectiveness of TTFields.
format Online
Article
Text
id pubmed-6200060
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Future Medicine Ltd
record_format MEDLINE/PubMed
spelling pubmed-62000602018-10-26 Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients Guzauskas, Gregory F Salzberg, Marc Wang, Bruce CM CNS Oncol Research Article AIM: To estimate the mean lifetime survival benefit, an essential component of health economic evaluations in oncology, of adding tumor treating fields (TTFields) to maintenance temozolomide (TMZ) for newly diagnosed glioblastoma patients. METHODS: We integrated EF-14 trial data with glioblastoma epidemiology data. The model provided for an evidence-based approach to estimate lifetime survival for the material number of EF-14 trial patients still alive at 5 years. RESULTS & CONCLUSION: Patients treated with TTFields and TMZ had an incremental mean lifetime survival of 1.8 years (TTFields/TMZ: 4.2 vs TMZ alone: 2.4). Patients alive at year 2 after starting TTFields had a 20.7% probability of surviving to year 10. The results presented here provide the required incremental survival benefit necessary for a future assessment of the incremental cost–effectiveness of TTFields. Future Medicine Ltd 2018-08-20 /pmc/articles/PMC6200060/ /pubmed/30124334 http://dx.doi.org/10.2217/cns-2018-0010 Text en © 2018 Gregory F Guzauskas, Marc Salzberg, & Bruce CM Wang This work is licensed under a Creative Commons Attribution-NonCommercial NonDerivative 4.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Research Article
Guzauskas, Gregory F
Salzberg, Marc
Wang, Bruce CM
Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients
title Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients
title_full Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients
title_fullStr Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients
title_full_unstemmed Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients
title_short Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients
title_sort estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200060/
https://www.ncbi.nlm.nih.gov/pubmed/30124334
http://dx.doi.org/10.2217/cns-2018-0010
work_keys_str_mv AT guzauskasgregoryf estimatedlifetimesurvivalbenefitoftumortreatingfieldsandtemozolomidefornewlydiagnosedglioblastomapatients
AT salzbergmarc estimatedlifetimesurvivalbenefitoftumortreatingfieldsandtemozolomidefornewlydiagnosedglioblastomapatients
AT wangbrucecm estimatedlifetimesurvivalbenefitoftumortreatingfieldsandtemozolomidefornewlydiagnosedglioblastomapatients